Non Hodgkin Lymphoma Clinical Trial

A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin’s Lymphoma

Summary

A total of 506 patients, 253 per arm, will be enrolled at 30 to 40 sites in the United States and Europe.

Patients will be randomly assigned to one of two treatment arms. In Arm A, patients will receive 375 mg/m2 of rituximab (US, Canada - Rituxan®; EU - Mabthera®), given as an IV infusion once weekly for 4 weeks. In Arm B, patients will receive Iodine I 131 Tositumomab therapy. For Arm B, patients undergo a two-phase treatment. In the first phase, termed the "dosimetric dose," patients will receive an infusion of unlabeled Tositumomab (450 mg) immediately followed by an infusion of Tositumomab (35 mg) that has been labeled with 5 mCi (0.18 GBq) of iodine 131. Whole body gamma camera scans will be obtained three times (Day 0, Day 2, 3, or 4, and Day 6 or 7) following the dosimetric dose. Using the dosimetric data from these three imaging timepoints, the patient's weight, and platelet count, a patient-specific administered activity of iodine I 131 Tositumomab (expressed in mCi or GBq) will be calculated to deliver the desired total body dose of radiation (65 or 75 cGy). In the second phase, termed the "therapeutic dose," patients in Arm B will receive an infusion of unlabeled Tositumomab (450 mg) immediately followed by an infusion of the patient-specific administered activity of Iodine 131-conjugated Tositumomab (35 mg).

Patients on study will be followed for response and safety at Week 7, Week 13, and every 3 months for the first and second years, every 6 months for the third year, and then annually for the fourth and fifth years. Patients will be followed for safety only annually for years 6-10.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria

A histologically confirmed diagnosis of follicular lymphoma, Grade I, II, or III (WHO/REAL Classification) (follicular, small cleaved; follicular, mixed small-cleaved and large-cell; or follicular large-cell lymphoma in the International Working Formulation).
Recurrent lymphoma after one or two qualifying therapy regimen(s).
A performance status of at least 70% on the Karnofsky Scale.
An absolute neutrophil count > 1500 cells/mm3 and a platelet count > 100,000 cells/mm3.
Adequate renal function and adequate hepatic function.
Bi-dimensionally measurable disease with at least one lesion measuring > or equal to 2.0 x 2.0 cm (i.e., > 4.0 cm2) by CT scan.
HAMA negative.
At least 18 years of age.
Give written informed consent by signing an IRB/ethics committee approved informed consent form prior to study entry.

Exclusion Criteria

Histological transformation to diffuse,large cell lymphoma
More than 1 course of rituximab
Disease better treated with limited field therapy
Involvement of >25% of the intratrabecular marrow
Active infection
Significant cardiac disease
Prior ChemoRx, biological therapy, radiation Rx, or high dose systemic steroid therapy within 8 weeks
Prior radioimmunotherapy
History of another malignancy
HBsAg positivity
CNS involvement with lymphoma
Pregnant or nursing
Ascites by physical exam
Previous use of non-human monoclonal antibody therapy, known hypersensitive to murine proteins
Hydronephrosis
Radiotherapy to >25% of the blood forming marrow
Prior stem cell transplant
Failed stem cell harvest

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 3

Estimated Enrollment:

506

Study ID:

NCT00078598

Recruitment Status:

Unknown status

Sponsor:

Corixa Corporation

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 5 Locations for this study

See Locations Near You

Northside Hospital
Atlanta Georgia, 30342, United States More Info
Barry Boatman, RN
Contact
404-303-3355
[email protected]
Ronald Steis, MD
Principal Investigator
Medical Oncology/Hematology Associates
Dayton Ohio, 45409, United States More Info
Cathy Hull, RN
Contact
937-223-2183
Basel Yanes, MD
Principal Investigator
Madigan Army Medical Center
Tacoma Washington, 98431, United States More Info
Carol Dean, RN
Contact
253-968-3681
[email protected]
David E McCune, MD, MPH
Principal Investigator
St Mary Medical Center/Regional Cancer Center
Walla Walla Washington, 99362, United States More Info
Cathy McCauley, RN
Contact
509-522-5993
[email protected]
Matthew Sacks, MD
Principal Investigator
West Virginia University/Mary Babb Randolph Cancer Center
Morgantown West Virginia, 26506, United States More Info
Robin Weisenborn, MT, CCRC
Contact
304-293-3709
[email protected]
Solveig Ericson, MD, PhD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 3

Estimated Enrollment:

506

Study ID:

NCT00078598

Recruitment Status:

Unknown status

Sponsor:


Corixa Corporation

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider